Genevant

Genevant Sciences is a leading nucleic acid delivery solutions company with best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology. Our selective collaboration business model enables us to partner with innovative payload companies in the gene editing, and RNA editing, therapeutic and vaccine spaces to bring emerging technologies into and through the clinic.

Our leadership position, built over more than two decades focused on nucleic acid development and delivery, is reflected in the first approved RNA-LNP product (Onpattro® marketed by Alnylam) and the industry’s most robust and expansive LNP patent portfolio. Currently our research focus is to expand the therapeutic reach of LNPs to T cells, hematopoietic stem cells and other traditionally hard to reach tissues/cell types.

We are here to help you bring your nucleic acid-based medicines to patients!